- Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that the Company's 12 director nominees were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the 2022 fiscal year. In addition, shareholders supported the board-sponsored proposal to approve, on an advisory basis, the compensation of the Company's named executive officers.
In other voting, shareholders did not support the five shareholder-sponsored proposals.
"We thank all shareholders for their engagement and participation today and for their ongoing support for our Company. 2021 was a year in which Pfizer set all-time highs in all major areas of focus for our Company further cementing Pfizer as a scientific powerhouse capable of taking on the world's most devastating diseases," stated Albert Bourla, Pfizer Chairman and Chief Executive Officer.
He continued, "Looking ahead, we are well positioned to continue to deliver meaningful value for patients, investors and all stakeholders underpinned by the momentum of our business, the strength of our internal pipeline and our ability to deploy capital into growth-focused business development to access external science."
The final results are subject to verification by the independent inspectors of election. The final results will be reported on a Current Report on Form 8-K to be filed by Pfizer with the U.S. Securities and Exchange Commission in the next few days.
